Latham & Watkins LLP has bolstered its intellectual property litigation team by bringing on a partner from Desmarais LLP in Washington, D.C. This strategic hire strengthens Latham’s capabilities in high-stakes IP litigation. The new addition has been instrumental in representing GlaxoSmithKline Biologicals in its ongoing patent infringement suit against Moderna Inc., a case that has garnered significant attention in the legal community. Details about the hiring were announced by Latham on Tuesday, highlighting the firm’s commitment to enhancing its competitive edge in the ever-evolving IP landscape. Read more.
As reported in Law.com, the partner’s move to Latham comes at a time when the demand for top-tier IP litigators is surging, driven by the rapid pace of technological advancements and the corresponding increase in patent disputes. This trend has seen prominent law firms like Latham investing heavily in talent acquisition to better serve their clients’ complex legal needs in the intellectual property domain.
The partner’s expertise is expected to greatly benefit Latham’s existing clientele, which includes leading pharmaceutical, biotech, and technology firms. This is especially pertinent as many corporations are intensifying their focus on protecting intellectual property rights amid heightened competition and market pressures. A move like this often results in shifts within the legal industry, as firms vie for top talent to fortify their practices. A deeper analysis on the implications of IP law and recent trends in litigation is available in Law.com.
Latham’s latest recruit also demonstrates the firm’s strategic alignment with current market demands, showcasing its proactive approach to legal recruitment and emphasizing its status as a formidable player in the legal field. With the addition of seasoned experts, Latham aims to not only meet the present challenges posed by IP litigation but also anticipate and adapt to future shifts in the legal landscape.